'The Company has reviewed the commercialisation options for BTX 1701 and believes that the prescription market for a product with the profile of BTX 1701 is more commercially attractive than the over the counter (OTC) pathway, even though the latter is potentially faster and less costly. Prescription products attract 5 years of regulatory exclusivity from FDA (in addition to patent protection) and substantially higher pricing than OTC products and Botanix’s modelling supports undertaking a rapid development program for BTX 1701 which will ultimately result in FDA approval as a new chemical entity for acne. In light of this conclusion and in order to manage its risk of undertaking multiple concurrent clinical programs (with BTX 1503 and BTX 1204), Botanix is reviewing its plans to commence a small patient study in 4Q CY2017 and is likely to postpone further development until 1Q CY2018 following the receipt of data from the BTX 1503 study.'
BOT Price at posting:
4.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)